NRx Pharma furnishes new investor presentation
NRx Pharmaceuticals furnished an investor presentation under Regulation FD, making it available to investors without treating it as a filed Exchange Act document.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
NRx Pharmaceuticals, Inc. (NRXP) furnished an investor presentation under a Regulation FD disclosure. On September 8, 2026, company representatives used the presentation, which is included as Exhibit 99.1, in meetings with investors and other parties, and may continue to use it, in whole or in part, possibly with modifications.
The investor presentation and related Item 7.01 information are being furnished, not filed, so they are not subject to liabilities of Section 18 of the Exchange Act and are not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Presentation use date: September 8, 2026
Exhibit 99.1: Investor Presentation
Exhibit 104: Cover Page Inline XBRL tags
3 metrics
Presentation use date
September 8, 2026
Date representatives used the investor presentation with investors
Exhibit 99.1
Investor Presentation
Primary exhibit furnished with the Form 8-K
Exhibit 104
Cover Page Inline XBRL tags
Interactive data file embedded within the Inline XBRL document
Key Terms
Regulation FD, Emerging growth company, Inline XBRL, investor presentation
4 terms
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
investor presentation financial
"used the investor presentation furnished as Exhibit 99.1"
An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NRXP disclose in its September 8, 2026 Form 8-K?
NRx Pharmaceuticals disclosed that it used, and may continue to use, an investor presentation with investors and other parties. The presentation is furnished as Exhibit 99.1 under a Regulation FD disclosure item.
How is the NRXP investor presentation treated under the securities laws?
The investor presentation furnished by NRx Pharmaceuticals is treated as furnished, not filed under the Exchange Act. It is not subject to Section 18 liability and is not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Will NRx Pharmaceuticals (NRXP) continue using the September 2026 investor presentation?
NRx Pharmaceuticals states it may continue to use the investor presentation, in whole or in part and possibly with modifications, in future presentations to investors, analysts and other persons.
Where can investors find the NRXP investor presentation mentioned in the 8-K?
The investor presentation used by NRx Pharmaceuticals is attached to the Form 8-K as Exhibit 99.1. It is part of the Regulation FD disclosure section of the report.
Does the NRXP Form 8-K announce any new financial results or major transactions?
No. The Form 8-K focuses on furnishing an investor presentation under Regulation FD. It does not describe new financial results or major corporate transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2026
(Exact name of registrant as specified in its charter) |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
(Address of principal executive offices) | (Zip Code) |
(484 ) 254-6134
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.424) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of exchange on which registered |
||
The |
||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the “Company”) used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors and other persons. The Company may continue to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and other persons.
The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. | Description |
|
99.1 | Investor Presentation |
|
104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NRx Pharmaceuticals, Inc. | |||
Date: September 14, 2026 | By: | /s/ Jonathan Javitt | |
Name: | Jonathan Javitt | ||
Its: | Chief Executive Officer | ||
Exhibit 99.1
